NCT06033820View on ClinicalTrials.gov

Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 12, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

June 30, 2025

Conditions
Diffuse Large B-cell Lymphoma RecurrentDiffuse Large B Cell Lymphoma Refractory
Interventions
DRUG

ZR2-ICE

"* Drug: zanubrutinib Oral Capsule~* Drug: lenalidomide Oral Capsule~* Drug: R-ICE chemotherapy"

Trial Locations (1)

200127

RECRUITING

Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER